Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

PURPOSE: Evaluate the percentage of patients with prostate cancer treated with luteinizing hormone-releasing hormone analogues (LHRHa) that develop castration resistance after a follow-up period of 3 years. The secondary objective is to evaluate the variables potentially related to the progression t...

Descripción completa

Detalles Bibliográficos
Autores principales: Angulo, J. C., Ciria Santos, J. P., Gómez-Caamaño, A., Poza de Celis, R., González Sala, J. L., García Garzón, J. M., Galán-Llopis, J. A., Pérez Sampietro, M., Perrot, V., Planas Morin, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512882/
https://www.ncbi.nlm.nih.gov/pubmed/36057895
http://dx.doi.org/10.1007/s00345-022-04108-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512882/
https://www.ncbi.nlm.nih.gov/pubmed/36057895
http://dx.doi.org/10.1007/s00345-022-04108-x

Ejemplares similares